Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials

A method for co-administering a solid amorphous dispersion and a lipophilic microphase-forming material in vivo, comprising:

• (a) forming a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer;
• (b) providing a lipophilic microphase-forming material, wherein a mass ratio of said lipophilic microphase-forming material to said low-solubility drug is from 0.1 to 100;
• (c) administering said solid amorphous dispersion and said lipophilic microphase-forming material in a sufficient amount so as to provide concentration enhancement of said drug in a use environment relative to at least one of a first control composition and a second control composition;
• wherein
• (i) said first control composition consists essentially of an equivalent amount of said solid amorphous dispersion with no lipophilic microphase-forming material present;
• (ii) said second control composition consists essentially of an equivalent amount of said low-solubility drug in undispersed form with an equivalent amount of said lipophilic, microphase-forming material but with no concentration-enhancing polymer;
• and
• wherein said lipophilic microphase-forming material is water immiscible and said low-solubility drug has a partition coefficient Kp between said use environment and said lipophilic microphase-forming material of at least 0.02 wt %/Sxstal, where Sxstal is the maximum aqueous solubility of said low-solubility drug in wt %.